SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3588-3594. Prepublished online as a Blood First Edition Paper on December 7, 2006; DOI 10.1182/blood-2006-07-036848. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-07-036848v1 109/8/3588    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Crawley, C. Articles by Gahrton, G. Search for Related Content PubMed PubMed Citation Articles by Crawley, C. Articles by Gahrton, G. Related Collections Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning Charles Crawley1, Simona Iacobelli2, Bo Björkstrand3, Jane F. Apperley4, Dietger Niederwieser5, Gösta Gahrton, for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)3 1 Addenbrooke's Hospital, Cambridge, United Kingdom; 2 Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands; 3 Karolinska University Hospital, Huddinge, Stockholm, Sweden; 4 Imperial College, Hammersmith Hospital, London, United Kingdom; 5 University of Leipzig, Germany Despite the widespread adoption of reduced-intensity conditioning (RIC) for myeloma, there are few data comparing outcomes with RIC with myeloablative conditioning (MAC). We report the outcomes of patients undergoing allogeneic transplantations for myeloma and reported to the EBMT. A minimum data set was available on 320 RIC and 196 MAC allografts performed between 1998 and 2002. The RIC patients were older (51 vs 45 years) with more progressive disease (28% vs 21%) and more had received a prior transplant (76% vs 11%). In addition, there was a longer time to transplantation and an increased use of peripheral blood and T-cell depletion. For RIC and MAC, respectively, the nonrelapse mortality (NRM) at 2 years was 24% and 37% (P = .002); overall survival, 38.1% and 50.8% (not significant [ns]); and progression-free survival (PFS), 18.9% and 34.5% (P = .001). On multivariate analysis, RIC was associated with a reduction in NRM (HR, 0.5), but this was offset by an increase in relapse risk (HR, 2.0), and the conditioning intensity did not impact on overall survival or retain significance for PFS. These data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Nonmyeloablative allotransplantation for myeloma: light and shade Michele Cavo Blood 2007 109: 3134-3135. [Full Text] [PDF] This article has been cited by other articles: G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma Haematologica, November 1, 2007; 92(11): 1513 - 1518. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020